Penicillin and gentamicin are the usual initial antibiotics for the treatment of neonatal sepsis. Gentamicin, however, has several theoretical It has a wide spectrum of activity in vitro against most neonatal pathogens including Pseudomonas aeruginosa and also has no appreciable nephrotoxicity.12 In addition, adequate penetration into cerebrospinal fluid has been described.13
Neonatal sepsis, though often suspected, is difficult to prove. It is therefore necessary to study a large number of babies before a sufficient number of infections with unequivocal clinical importance may be documented. The (Table 3) .
Finally, there was one septicaemia with resistant organisms. This baby was receiving respiratory support for pulmonary interstitial emphysema and had received eight days of ceftazidime and five days of penicillin and gentamicin. Twenty four hours after antibiotics were stopped he deteriorated. In no cases were adverse changes seen in any biochemical or haematological values.
Discussion
This study was designed to evaluate experience with ceftazidime over a long period, treating a wide variety of infections. It was not a controlled study comparing ceftazidime with another antibiotic. Because of the variety of infection encountered in a neonatal unit, it was considered that such a study would give an inconclusive result.
Indeed, controlled studies8 9 comparing various antibiotic regimens have been inconclusive as regards the relative efficacy of the antibiotic because of the very low septicaemia rate and the variety of organisms in the groups compared. Also, certain open studies on the new cephalosporins"' 11 have concluded that the antibiotic was safe but because of only two cases of septicaemia in each study, this was not a true test. In our study there were 12 proved cases of septicaemia, and therefore some assessment of the effectiveness of ceftazidime may be made.
On the positive side, ceftazidime cured five of six babies with Gram negative septicaemia. The This study shows that ceftazidime is a good antibiotic to use for most neonatal infections. It is effective against Gram negative infections, it penetrates cerebrospinal fluid well, and its minimal toxicity obviates the need for blood monitoring.
Reservations exist about its role in the group B Pi haemolytic streptococcal infections, so its use as a single first line antibiotic is not recommended until more experience has been accumulated. 
